Skip to content

Clinical trials

Observational Diabetes, Gestational trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Diabetes, Gestational Phase: Observational Country / region: United States Clear all

56 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20061
20074
20082
20094
20101
20112
20124
20132
20144
20152
20162
20172
20181
20194
20202
20216
20222
20232
20241
20256
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed27
Unknown status8
Recruiting7
Withdrawn4
Active, not recruiting4
Terminated3
Enrolling by invitation2
Not yet recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Brigham and Women's Hospital3
Ohio State University3
University of Colorado, Denver3
Icahn School of Medicine at Mount Sinai2
Northwestern University2
University of California, Davis2
University of Minnesota2
University of Tennessee Graduate School of Medicine2
VeraLight, Inc.2
Arkansas Children's Hospital Research Institute1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Diabetes, Gestational56
Diabetes Mellitus, Type 210
Obesity8
Diabetes Mellitus6
Insulin Resistance6
Pregnancy Complications6
Pre-Eclampsia5
Pregnancy in Obesity4
Diabetes Mellitus, Type 13
Glucose Intolerance3

Trials

Showing 1 to 25 of 56. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.